Skip to main content
. 2017 Dec 27;315(4):F834–F843. doi: 10.1152/ajprenal.00554.2017

Fig. 7.

Fig. 7.

Effects of addition of the pharmacological inhibitor of MLCK (ML-7), the inhibitor of MLCP (calyculin A), and a Rho-K-Inhibitor (Y-27632) to the perfusate on renin secretion (A) and flow (B) of isolated mouse kidneys perfused at a constant pressure of 90 mmHg. Data were obtained after a stable plateau phase had been reached. ML-7 inhibits MLCK and leads to an increase in flow rate and renin secretion rate comparable to the effects of EGTA alone (control) and EGTA in presence of ML-7. Inhibition of Rho-K by Y-27632 also caused a strong increase in perfusate flow but no increase in renin secretion. Lowering of the extracellular calcium concentration by EGTA in the presence of Y-27632 led to no further increase in perfusate flow but to an increase in renin secretion to levels seen in the absence of Y-27632 (control). Inhibition of the MLCP by calyculin A caused a strong decrease of both perfusate flow and renin secretion. In the presence of calyculin A, lowering of the extracellular calcium concentration by EGTA exerted only moderate vasodilatation effects as indicated by the increase of perfusate flow while renin secretion remained suppressed. *P < 0.05; data are means ± SE of 4 kidneys.